Literature DB >> 11820299

New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity.

Hans K Lorenzo1, Jose Teixeira, Nima Pahlavan, V Matt Laurich, Patricia K Donahoe, David T MacLaughlin.   

Abstract

We have established a new method to purify Müllerian inhibiting substance (MIS) with higher purity and recovery over existing procedures. Recombinant human MIS was expressed in Chinese hamster ovary cells and secreted into chemically defined serum-free media. The secreted products were concentrated by either precipitation with ammonium sulfate or lectin-affinity chromatography, each of which was followed by anion-exchange chromatography. Further separation of the active carboxy-terminal domain of MIS was achieved after cleavage by plasmin followed by lectin-affinity chromatography. This method may be applicable to other members of the transforming growth factor beta family with which MIS shares sequence homology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11820299     DOI: 10.1016/s0378-4347(01)00436-4

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  16 in total

1.  Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

Authors:  Elizabeth J Renaud; David T MacLaughlin; Esther Oliva; Bo R Rueda; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-23       Impact factor: 11.205

2.  Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.

Authors:  Seong Jin Hwang; Min Jung Suh; Joo Hee Yoon; Mee Ran Kim; Ki Sung Ryu; Suk Woo Nam; Patricia K Donahoe; David T Maclaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2011-05-13       Impact factor: 5.650

3.  AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.

Authors:  Motohiro Kano; Amanda E Sosulski; LiHua Zhang; Hatice D Saatcioglu; Dan Wang; Nicholas Nagykery; Mary E Sabatini; Guangping Gao; Patricia K Donahoe; David Pépin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

Review 4.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

5.  Focal Mullerian duct retention in male mice with constitutively activated beta-catenin expression in the Mullerian duct mesenchyme.

Authors:  Pradeep S Tanwar; LiHua Zhang; Yoshihiro Tanaka; Makoto M Taketo; Patricia K Donahoe; Jose M Teixeira
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

6.  Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Authors:  Rafael Pieretti-Vanmarcke; Patricia K Donahoe; Lisa A Pearsall; Daniela M Dinulescu; Denise C Connolly; Elkan F Halpern; Michael V Seiden; David T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

7.  Regulation of gonadotropin gene expression by Mullerian inhibiting substance.

Authors:  Grégoy Y Bédécarrats; Francis H O'Neill; Errol R Norwitz; Ursula B Kaiser; Jose Teixeira
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-23       Impact factor: 11.205

8.  An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance.

Authors:  D Pépin; M Hoang; F Nicolaou; K Hendren; L A Benedict; A Al-Moujahed; A Sosulski; A Marmalidou; D Vavvas; P K Donahoe
Journal:  Technology       Date:  2013-09

9.  c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.

Authors:  Nina Renlund; Rafael Pieretti-Vanmarcke; Francis H O'Neill; LiHua Zhang; Patricia K Donahoe; Jose Teixeira
Journal:  Endocrinology       Date:  2007-10-18       Impact factor: 4.736

10.  AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.

Authors:  David Pépin; Amanda Sosulski; Lihua Zhang; Dan Wang; Vinod Vathipadiekal; Katherine Hendren; Caroline M Coletti; Aaron Yu; Cesar M Castro; Michael J Birrer; Guangping Gao; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.